Home - Open Targets

Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or the Open Targets Genetics portal which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.

Find targets for a given disease
Visit the Open Targets Platform Discover genetic evidence for targets
Visit Open Targets Genetics Explore our experimental projects
Read our research publications

News

Human colorectal cancer cells stained purple, blue, and green under a microscope.

Bowel cancer mutations that impact immunotherapy identified

19 January 2023

Researchers used CRISPR and mini tumours to discover more about how cancer develops and responds to the body’s immune response.

A new library documenting hundreds of mutations can help to explain why some cancers don’t respond to immunotherapies, and highlights potential pathways that could be drug targets in the future.

The researchers, from the Wellcome Sanger Institute, Open Targets, and collaborators, used CRISPR gene editing technology and mini tumours...

Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.